×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Ventricular Assist Devices Market

ID: MRFR/HC/49688-HCR
200 Pages
Rahul Gotadki
October 2025

South America Ventricular Assist Devices Market Research Report By Product Type (Left Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist Device), By Type of Flow (Continuous Flow, Pulsatile Flow), By Design (Implantable Ventricular Assist Device, Transcutaneous Ventricular Assist Device), By Application (Destination Therapy, Bridging Therapy) and By Regional (Brazil, Mexico, Argentina, Rest of South America)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Ventricular Assist Devices Market Infographic
Purchase Options

South America Ventricular Assist Devices Market Summary

As per MRFR analysis, the South America ventricular assist-devices market was estimated at 180.0 USD Million in 2024. The South America ventricular assist-devices market is projected to grow from 195.64 USD Million in 2025 to 450.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.69% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The South America ventricular assist-devices market is poised for growth driven by technological advancements and increasing healthcare investments.

  • Brazil remains the largest market for ventricular assist-devices, reflecting a robust healthcare infrastructure.
  • Mexico is emerging as the fastest-growing region, indicating a rising demand for advanced cardiac solutions.
  • Technological innovations in device design are enhancing the efficacy and safety of ventricular assist-devices.
  • The rising incidence of heart failure and supportive reimbursement policies are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 180.0 (USD Million)
2035 Market Size 450.0 (USD Million)

Major Players

Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cleveland Heart (US), ReliantHeart (US), Syncardia (US), Getinge (SE), CardiacAssist (US)

South America Ventricular Assist Devices Market Trends

The ventricular assist-devices market in South America is currently experiencing notable growth, driven by an increasing prevalence of heart diseases and a rising aging population. The demand for advanced cardiac support solutions is escalating, as healthcare providers seek to improve patient outcomes and enhance quality of life. Innovations in technology, such as miniaturization and improved biocompatibility of devices, are also contributing to market expansion. Furthermore, government initiatives aimed at improving healthcare infrastructure and access to advanced medical technologies are likely to bolster the adoption of these devices across the region. In addition, the market appears to be influenced by a growing awareness of heart health among the population, leading to earlier diagnosis and treatment of cardiovascular conditions. This trend is complemented by the establishment of specialized cardiac care centers, which are increasingly equipped with state-of-the-art ventricular assist devices. As the healthcare landscape evolves, the focus on personalized medicine and patient-centric approaches may further drive innovation and investment in the ventricular assist-devices market. Overall, the outlook for this market in South America seems promising, with potential for continued growth and development in the coming years.

Technological Advancements

The ventricular assist-devices market is witnessing rapid technological advancements, particularly in device design and functionality. Innovations such as wireless monitoring systems and improved battery life are enhancing the usability and effectiveness of these devices. This trend is likely to attract more healthcare providers to adopt advanced solutions, thereby improving patient outcomes.

Regulatory Support

Regulatory bodies in South America are increasingly supportive of the ventricular assist-devices market, streamlining approval processes for new technologies. This regulatory environment encourages manufacturers to invest in research and development, potentially leading to a wider range of options for patients and healthcare providers.

Increased Investment in Healthcare Infrastructure

There is a growing trend of investment in healthcare infrastructure across South America, which is expected to positively impact the ventricular assist-devices market. Enhanced facilities and resources will likely facilitate better access to advanced cardiac care, thereby increasing the adoption of these life-saving devices.

South America Ventricular Assist Devices Market Drivers

Rising Incidence of Heart Failure

The increasing prevalence of heart failure in South America is a primary driver for the ventricular assist-devices market. According to recent health statistics, heart failure affects approximately 6-10% of the adult population in this region. This growing patient population necessitates advanced treatment options, including ventricular assist devices, to improve survival rates and quality of life. As healthcare providers seek effective solutions to manage heart failure, the demand for these devices is expected to rise significantly. The ventricular assist-devices market is likely to experience substantial growth as hospitals and clinics invest in these technologies to address the urgent needs of heart failure patients. Furthermore, the aging population in South America contributes to this trend, as older adults are more susceptible to cardiovascular diseases, thereby increasing the market potential for ventricular assist devices.

Supportive Reimbursement Policies

The establishment of favorable reimbursement policies for ventricular assist devices in South America is a significant driver for the market. Governments and insurance providers are increasingly recognizing the value of these devices in improving patient outcomes and reducing long-term healthcare costs. As reimbursement frameworks evolve to cover the costs associated with ventricular assist devices, healthcare facilities are more likely to adopt these technologies. This trend is expected to enhance the accessibility of devices for patients who require them, thereby expanding the ventricular assist-devices market. Furthermore, the potential for cost savings associated with reduced hospital readmissions and improved patient management may encourage further investment in these devices by healthcare systems across the region.

Technological Innovations in Device Design

Innovations in the design and functionality of ventricular assist devices are propelling the market forward in South America. Recent advancements have led to the development of smaller, more efficient devices that offer improved patient outcomes. For instance, the introduction of continuous-flow devices has revolutionized treatment options, providing patients with better mobility and quality of life. The ventricular assist-devices market is witnessing a surge in research and development activities aimed at enhancing device performance and biocompatibility. As manufacturers focus on integrating advanced materials and smart technologies, the market is expected to expand. The potential for these innovations to reduce complications and improve patient adherence to treatment regimens further underscores their importance in the evolving landscape of cardiac care in South America.

Collaboration Between Healthcare Stakeholders

Collaboration among various stakeholders in the healthcare sector is fostering growth in the ventricular assist-devices market in South America. Partnerships between device manufacturers, healthcare providers, and research institutions are facilitating the development and dissemination of innovative technologies. These collaborations often lead to clinical trials and studies that validate the efficacy of ventricular assist devices, thereby enhancing their acceptance in clinical practice. The ventricular assist-devices market benefits from these synergies, as they promote knowledge sharing and resource allocation towards improving patient care. Additionally, such collaborations may result in the establishment of specialized centers for heart failure management, further driving the demand for ventricular assist devices in the region.

Growing Awareness and Education on Heart Health

In South America, there is a notable increase in awareness regarding heart health and the available treatment options for heart failure. Public health campaigns and educational initiatives are playing a crucial role in informing patients and healthcare professionals about the benefits of ventricular assist devices. This heightened awareness is likely to drive demand within the ventricular assist-devices market, as more patients seek advanced therapies for managing their conditions. Additionally, healthcare providers are becoming more knowledgeable about the indications for device implantation, leading to earlier referrals and increased utilization of these technologies. As a result, the market is expected to grow as patients become more proactive in seeking treatment options that can enhance their quality of life and longevity.

Market Segment Insights

By Product Type: Left Ventricular Assist Device (Largest) vs. Right Ventricular Assist Device (Fastest-Growing)

In the current landscape, the Left Ventricular Assist Device (LVAD) holds a significant market share, establishing itself as the largest segment due to its extensive application in advanced heart failure treatment. This device is favored for its effectiveness and efficiency in prolonging the life of patients, leading to a strong demand that significantly impacts the overall dynamics of the product type segment. Conversely, the Right Ventricular Assist Device (RVAD) is rapidly gaining traction as the fastest-growing segment, driven by increasing awareness and advancements in technology that improve its functionality and reliability. The growth trends for these devices are closely linked to the rise in heart failure cases and the technical innovations enhancing device performance. The RVAD’s expanding acceptance in critical care settings showcases its emerging role in supporting right ventricular function, which was previously less prioritized. As healthcare systems in South America continue to evolve, both LVAD and RVAD are expected to benefit from improved healthcare infrastructure and increasing investments in cardiac care technologies, driving their respective growth trajectories further.

Product Type: LVAD (Dominant) vs. RVAD (Emerging)

The Left Ventricular Assist Device (LVAD) is currently the dominant force in this segment, known for its pivotal role in the management of severe heart failure. Its proven efficacy in improving survival rates and quality of life for patients has cemented its position in the market. LVADs are characterized by their robust engineering and extensive clinical validation, making them a preferred choice for long-term support. On the other hand, the Right Ventricular Assist Device (RVAD) represents an emerging opportunity, particularly as advancements in design and technology enhance its application. RVADs are increasingly utilized to address right-sided heart failure, an area that is gaining clinical focus. Their growing adoption is indicative of a shift towards comprehensive cardiac support solutions, thereby expanding the treatment landscape.

By Type of Flow: Continuous Flow (Largest) vs. Pulsatile Flow (Fastest-Growing)

In the South America ventricular assist-devices market, Continuous Flow has emerged as the largest segment, capturing a significant share due to its widespread acceptance and proven efficacy in long-term support for patients. Pulsatile Flow, while smaller, is gaining traction as demand for innovative solutions that mimic natural heart rhythms increases. This growth reflects a shift towards more adaptable and responsive technologies in heart support devices. The growth trends for these segments indicate a progressive market with evolving consumer preferences. Continuous Flow devices are established and preferred in clinical settings, enabling steady blood circulation without the need for frequent interventions. Conversely, Pulsatile Flow is perceived as an emerging technology driven by advancements in engineering and patient feedback, leading to rapid development and adoption in the market.

Flow Type: Continuous (Dominant) vs. Pulsatile (Emerging)

Continuous Flow ventricular assist devices are characterized by their consistent, non-pulsatile output, which has made them the dominant choice in long-term mechanical support for patients with advanced heart failure. These devices are less complex and often have lower maintenance requirements, providing reliable performance and better quality of life for patients. On the other hand, Pulsatile Flow devices are gaining momentum as an emerging alternative, offering the advantage of simulating natural heart function. This segment appeals to patients seeking devices that provide a more physiological way of blood circulation, and ongoing advancements in technology are expected to enhance their market viability.

By Design: Implantable Ventricular Assist Device (Largest) vs. Transcutaneous Ventricular Assist Device (Fastest-Growing)

In the South America ventricular assist-devices market, the Implantable Ventricular Assist Device segment holds a significant market share, being the preferred choice among medical professionals and patients alike. Its established technology and reliability make it a dominant player, capturing the majority of the market. Conversely, the Transcutaneous Ventricular Assist Device has been gaining traction, with an emerging presence due to its innovative design and non-invasive application, appealing to a specific patient demographic that seeks alternative treatment options. Growth trends show a robust continuation for both segments, driven by advancements in technology and increasing prevalence of cardiovascular diseases. The rising demand for long-term solutions is propelling the Implantable Ventricular Assist Device forward, while the swift adoption of the Transcutaneous variant indicates its potential to disrupt traditional treatment pathways. Factors such as improved patient outcomes, greater awareness, and ongoing research are expected to further enhance growth in the upcoming years.

Implantable Ventricular Assist Device (Dominant) vs. Transcutaneous Ventricular Assist Device (Emerging)

The Implantable Ventricular Assist Device is characterized by its robustness and long-term usability, making it a go-to option for patients requiring durable heart support solutions. It is preferred in advanced heart failure treatments due to its proven efficacy and established clinical pathways. In contrast, the Transcutaneous Ventricular Assist Device is recognized for its ease of use and non-invasive nature, appealing especially to patients who prefer less invasive interventions. This emerging technology addresses a crucial need for temporary support, especially during recovery phases, showcasing its advantage in specific clinical scenarios. As both segments contribute uniquely to the South America market, their co-existence highlights the diverse needs of patients and healthcare providers.

By Application: Destination Therapy (Largest) vs. Bridging Therapy (Fastest-Growing)

Within the application segment, Destination Therapy has established itself as the largest contributor to the market, driven by a growing patient population with advanced heart failure requiring long-term support. Bridging Therapy is rapidly gaining traction, appealing to a significant portion of clinicians as a temporary measure for patients awaiting transplants, contributing to its fast growth in adoption rates. The market dynamics are shifting as advancements in technology and techniques enhance the efficacy of ventricular assist devices. Factors such as increased awareness about heart health, rising incidences of heart diseases, and the growing elderly population are propelling the demand for both Destination and Bridging Therapies. Innovations in device design and patient management protocols are expected to further drive growth in this critical segment.

Therapeutic Approach: Destination Therapy (Dominant) vs. Bridging Therapy (Emerging)

Destination Therapy represents a dominant approach within the market, aimed at providing long-term care for patients who are not candidates for heart transplant. This approach enhances quality of life and provides significant survival benefits, making it a preferred choice for clinicians. On the other hand, Bridging Therapy is viewed as an emerging solution, primarily used to stabilize patients while they await heart transplantation. It offers temporary support and is increasingly recognized for its ability to manage acute heart failure situations effectively. Both therapeutic approaches are essential in addressing the needs of patients with severe cardiac conditions, but they serve distinct roles that complement each other in clinical practice.

Get more detailed insights about South America Ventricular Assist Devices Market

Regional Insights

Brazil : Robust Growth and Innovation Hub

Brazil holds a commanding 90.0% market share in the South American ventricular assist devices market, driven by increasing cardiovascular diseases and a growing elderly population. Government initiatives, such as the National Health System's focus on advanced medical technologies, have bolstered demand. The regulatory environment is supportive, with streamlined approval processes for innovative devices, enhancing market accessibility. Infrastructure improvements in healthcare facilities further facilitate device adoption.

Mexico : Increasing Demand for Cardiac Solutions

Key markets include Mexico City and Guadalajara, where major hospitals are adopting advanced cardiac technologies. The competitive landscape features players like Medtronic and Abbott, who are investing in local partnerships. The business environment is favorable, with increasing private sector involvement in healthcare, driving innovation and competition in the ventricular assist devices sector.

Argentina : Focus on Healthcare Accessibility

Buenos Aires and Córdoba are pivotal markets, with numerous hospitals adopting advanced cardiac technologies. Major players like Boston Scientific and Terumo are establishing a strong presence, enhancing competition. The local market dynamics are characterized by a mix of public and private healthcare providers, fostering a collaborative environment for innovation in cardiac care.

Rest of South America : Varied Growth Across Regions

Key markets include Santiago and Bogotá, where healthcare facilities are increasingly adopting advanced technologies. The competitive landscape features both local and international players, including Getinge and Syncardia. The business environment varies significantly, with some regions facing economic constraints that impact healthcare spending, while others are experiencing rapid growth in cardiac care.

South America Ventricular Assist Devices Market Regional Image

Key Players and Competitive Insights

The competitive dynamics within the ventricular assist-devices market in South America reflect a landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Abbott (US), Medtronic (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott (US) appears to focus on expanding its product portfolio through technological advancements, while Medtronic (US) emphasizes strategic partnerships to bolster its distribution channels. Boston Scientific (US) seems to be investing heavily in research and development, aiming to introduce next-generation devices that cater to the evolving needs of patients and healthcare providers. Collectively, these strategies contribute to a competitive environment that is increasingly driven by innovation and collaboration.

In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with regional regulatory requirements. The market structure is moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they leverage their resources and expertise to shape market trends and consumer preferences.

In October 2025, Abbott (US) announced the launch of a new ventricular assist device designed to improve patient outcomes through enhanced biocompatibility. This strategic move is significant as it underscores Abbott's commitment to innovation and positions the company to capture a larger share of the market by addressing critical patient needs. The introduction of this device is likely to strengthen Abbott's competitive edge, particularly in regions where patient outcomes are a primary concern.

In September 2025, Medtronic (US) entered into a partnership with a leading South American healthcare provider to enhance the distribution of its ventricular assist devices. This collaboration is strategically important as it allows Medtronic to leverage local expertise and infrastructure, thereby improving access to its products. Such partnerships are indicative of a broader trend where companies seek to establish strong local ties to navigate the complexities of regional markets effectively.

In August 2025, Boston Scientific (US) completed the acquisition of a smaller firm specializing in advanced materials for medical devices. This acquisition is pivotal as it not only expands Boston Scientific's technological capabilities but also enhances its competitive positioning in the market. By integrating these advanced materials into its product offerings, the company is likely to improve the performance and reliability of its devices, thereby attracting a more extensive customer base.

As of November 2025, the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in product development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving operational efficiencies. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological innovation and supply chain reliability. This transition suggests that companies that prioritize R&D and strategic partnerships will likely emerge as leaders in the market.

Key Companies in the South America Ventricular Assist Devices Market market include

Industry Developments

In recent developments within the South America Ventricular Assist Devices Market, companies such as Getinge and Boston Scientific have been enhancing their product portfolios to address the increasing demand for heart failure management solutions in this region. Thoratec and Medtronic have expanded their operations to improve access to ventricular assist devices in Brazil and Argentina, capitalizing on the growing healthcare infrastructure. Moreover, in March 2023, the Cleveland Clinic announced a collaboration with Syncardia to further innovate in the area of destination therapy for patients with advanced heart failure, reinforcing their commitment to advancing medical solutions in South America. 

In terms of mergers and acquisitions, Abbott Laboratories has made headlines for its acquisition of CardiacAssist in December 2022, aimed at expanding its offerings in circulatory support technologies. Fresenius Kabi and LivaNova continue to explore strategic partnerships to enhance their market share. Over the past two to three years, the market has witnessed significant growth, driven by increasing incidences of cardiovascular diseases and supportive government policies aimed at improving healthcare access, which have collectively propelled advancements in this vital sector.

Future Outlook

South America Ventricular Assist Devices Market Future Outlook

The ventricular assist-devices market is projected to grow at an 8.69% CAGR from 2024 to 2035, driven by technological advancements, increasing heart failure prevalence, and rising healthcare investments.

New opportunities lie in:

  • Development of portable ventricular assist devices for home care settings.
  • Partnerships with hospitals for integrated patient management solutions.
  • Expansion into emerging markets with tailored financing options for healthcare providers.

By 2035, the market is expected to achieve substantial growth, reflecting increased adoption and innovation.

Market Segmentation

South America Ventricular Assist Devices Market Design Outlook

  • Implantable Ventricular Assist Device
  • Transcutaneous Ventricular Assist Device

South America Ventricular Assist Devices Market Application Outlook

  • Destination Therapy
  • Bridging Therapy

South America Ventricular Assist Devices Market Product Type Outlook

  • Left Ventricular Assist Device (LVAD)
  • Right Ventricular Assist Device (RVAD)
  • Biventricular Assist Device (BIVAD)

South America Ventricular Assist Devices Market Type of Flow Outlook

  • Continuous Flow
  • Pulsatile Flow

Report Scope

MARKET SIZE 2024180.0(USD Million)
MARKET SIZE 2025195.64(USD Million)
MARKET SIZE 2035450.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)8.69% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies Profiled["Abbott (US)", "Medtronic (US)", "Boston Scientific (US)", "Terumo (JP)", "Cleveland Heart (US)", "ReliantHeart (US)", "Syncardia (US)", "Getinge (SE)", "CardiacAssist (US)"]
Segments CoveredProduct Type, Type of Flow, Design, Application
Key Market OpportunitiesEmerging technologies in ventricular assist-devices enhance patient outcomes and drive market growth opportunities.
Key Market DynamicsRising demand for ventricular assist devices in South America driven by regulatory support and technological advancements.
Countries CoveredBrazil, Mexico, Argentina, Rest of South America

Leave a Comment

FAQs

What is the expected market size of the South America Ventricular Assist Devices Market in 2024?

The South America Ventricular Assist Devices Market is expected to be valued at 195.0 million USD in 2024.

What is the projected market size for the South America Ventricular Assist Devices Market by 2035?

By 2035, the market value for South America Ventricular Assist Devices is projected to reach 430.0 million USD.

What is the expected CAGR for the South America Ventricular Assist Devices Market between 2025 and 2035?

The South America Ventricular Assist Devices Market is expected to experience a CAGR of 7.454% from 2025 to 2035.

Which region holds the largest market share in the South America Ventricular Assist Devices Market in 2024?

In 2024, Brazil holds the largest market share in the South America Ventricular Assist Devices Market, valued at 55.0 million USD.

What is the estimated market size for Right Ventricular Assist Devices in 2024?

The market size for Right Ventricular Assist Devices is estimated to be 60.0 million USD in 2024.

What growth is anticipated for the Biventricular Assist Device segment by 2035?

The Biventricular Assist Device segment is expected to grow to 120.0 million USD by 2035.

Who are the key players in the South America Ventricular Assist Devices Market?

Key players include Getinge, Boston Scientific, Thoratec, Cleveland Clinic, and Abbott Laboratories.

What is the market size for the South America Ventricular Assist Devices Market in Argentina by 2035?

By 2035, the market size for the Ventricular Assist Devices in Argentina is projected to be 70.0 million USD.

What future trends are anticipated in the South America Ventricular Assist Devices Market?

Emerging trends may include advancements in device technology and increased demand for heart failure treatments.

What is the market size of Rest of South America for Ventricular Assist Devices in 2024?

The market size for Rest of South America in Ventricular Assist Devices is estimated at 65.0 million USD in 2024.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions